Acacia Research Corporation — Q2 2015 Form 10-Q
Reporting period: Three and six months ended June 30, 2015. Acacia’s operating subsidiaries invest in, license and enforce patent rights, generally earning revenue from license agreements. Financial figures below are in U.S. dollars; dollar amounts are in millions unless noted.
Financial results and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $40.3 | $50.1 | $74.5 | $62.7 |
| Operating income (loss) | $1.0 | $(8.2) | $(12.6) | $(34.3) |
| Net loss attributable to Acacia | $(3.7) | $(12.9) | $(16.8) | $(37.4) |
| Basic and diluted loss per share | $(0.08) | $(0.27) | $(0.35) | $(0.78) |
- Calculated operating margin was approximately 2.5% in Q2 2015 versus negative 16.4% in Q2 2014; for the first half it was negative 16.9% versus negative 54.7%. The filing does not report a separate gross-margin measure.
- Q2 revenue fell 19%, while first-half revenue rose 19%. Acacia executed 20 agreements in Q2 and 43 in the first half, compared with 15 and 35, respectively, in the prior-year periods.
- At June 30, cash and cash equivalents were $119.1, short-term investments $37.1, and restricted cash $10.7. Cash and investments excluding restricted cash totaled $156.2; including restricted cash, they totaled $166.9.
- First-half operating cash flow was a use of $6.4, compared with a use of $0.6 in 2014. Investing activities provided $2.9, including $18.7 of patent investments; financing activities used $11.8, mainly for $12.7 of dividends. Cash and cash equivalents declined $15.4 to $119.1.
- Working capital, including restricted cash, was $179.0. Current assets were $210.7 and current liabilities $31.7. The company reported no long-term debt. Operating lease commitments totaled $7.3.
- Patents, net, were $262.3; goodwill was $30.1; total assets were $504.0; and total stockholders’ equity was $470.8.
Material changes and management commentary
- Q2 revenue decreased primarily because average revenue per agreement declined, partly offset by more agreements. Average revenue per agreement was approximately $2.0 million versus $3.3 million a year earlier. First-half growth primarily reflected a higher number of agreements.
- Q2 operating costs and expenses declined 33%, to $39.3. Inventor royalties and contingent legal fees together fell 62%, principally due to the mix of revenue-generating portfolios and recovery of upfront advances. Lower patent amortization, litigation and licensing costs, and general and administrative expenses also supported the quarter’s return to operating income.
- First-half operating costs and expenses declined 10%, to $87.2. Lower amortization, general and administrative expense, and litigation and licensing expense contributed to a narrower loss; combined inventor royalties and contingent legal fees increased 3%.
- Management said revenue can vary significantly by quarter because of agreement size and timing, litigation and negotiations, portfolio maturity, and other factors; it does not manage for smooth sequential growth. It described a strategic shift toward fewer, higher-quality patent portfolios. No specific revenue or earnings guidance was provided.
- Management believed available cash, investments and anticipated operating cash flows would meet requirements through at least August 2016. It cautioned that unexpected cash needs or inability to obtain financing on acceptable terms could constrain business plans.
- The board approved a $0.125-per-share quarterly dividend payable August 31, 2015. The stated policy anticipated $0.50 per share annually, but future dividends remain at the board’s discretion.
Risks, contingencies and unusual items
- Revenue and receivables are concentrated: one licensee generated 74% of Q2 revenue and represented approximately 80% of accounts receivable at June 30. The filing said most of those receivables were collected in July.
- A $10.7 million cash deposit was restricted to secure a bank guarantee supporting enforcement of a German patent injunction. The guarantee may expose the subsidiary to payment claims if the ruling is successfully appealed or amended; it renews automatically unless extinguished under applicable law. Its stated annual fee is 1.15%.
- A federal court deemed a 2013 lawsuit exceptional; the subsidiary challenged requested amounts and appealed. The company recorded $426,000 of expense in the first half. Separately, a California insurance-fraud complaint was dismissed with prejudice in Acacia’s favor in March 2015.
- Patent enforcement carries litigation-cost, adverse-ruling, sanctions, fee-shifting and regulatory risks. Management expects patent legal expenses to fluctuate and anticipates costs associated with trial dates, international enforcement and portfolio prosecution.
- A stock-price decline triggered an interim goodwill impairment test. Acacia concluded reporting-unit fair value exceeded carrying value and recorded no goodwill impairment at June 30. Management noted that revised revenue or cost expectations could lead to future patent or goodwill impairment charges.
- Short-term investments had $190,000 of gross unrealized losses at June 30; management reported no credit impairment and said it had the ability and intent to hold the securities. The filing also disclosed approximately $2.1 million of unrecognized tax benefits.
Most important facts for investors to verify
- Whether the unusually high customer and accounts-receivable concentrations persist, and whether major receivables are collected as expected.
- Whether the increase in agreement volume can offset lower average agreement value and the inherent volatility of licensing revenue.
- How patent litigation outcomes, legal spending and the German injunction affect cash flows, including the restricted deposit and guarantee exposure.
- Whether operating cash flow improves and the cash balance remains sufficient while funding patent investments and dividends.
- Whether future patent portfolio performance or valuation assumptions require impairment charges; also monitor the $2.1 million of unrecognized tax benefits.